These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9323539)

  • 1. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.
    Johnson MR; Yan J; Shao L; Albin N; Diasio RB
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(2):183-91. PubMed ID: 9323539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay.
    Liem LK; Choong LH; Woo KT
    Clin Biochem; 2002 May; 35(3):181-7. PubMed ID: 12074825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity.
    Déporte-Féty R; Picot M; Amiand M; Moreau A; Campion L; Lanoë D; Renée N; Milano G
    J Chromatogr B Biomed Sci Appl; 2001 Oct; 762(2):203-9. PubMed ID: 11678380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
    Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
    Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
    Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
    Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
    Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
    Duley JA; Nethersell AB
    Adv Exp Med Biol; 1998; 431():147-50. PubMed ID: 9598048
    [No Abstract]   [Full Text] [Related]  

  • 11. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
    Gardiner SJ; Begg EJ; Robinson BA
    Adverse Drug React Toxicol Rev; 2002; 21(1-2):1-16. PubMed ID: 12140902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
    Mattison LK; Ezzeldin H; Carpenter M; Modak A; Johnson MR; Diasio RB
    Clin Cancer Res; 2004 Apr; 10(8):2652-8. PubMed ID: 15102667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase activity in cancer patients.
    Fleming RA; Milano GA; Gaspard MH; Bargnoux PJ; Thyss A; Plagne R; Renée N; Schneider M; Demard F
    Eur J Cancer; 1993; 29A(5):740-4. PubMed ID: 8471333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
    Van Kuilenburg AB; Van Lenthe H; Tromp A; Veltman PC; Van Gennip AH
    Clin Chem; 2000 Jan; 46(1):9-17. PubMed ID: 10620566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.